Retatrutide is a next-generation triple agonist peptide targeting the GIP, GLP-1, and glucagon receptors. It is one of the most advanced compounds under research for extreme fat loss, insulin sensitivity, and appetite suppression. It combines the benefits of GLP-1 receptor agonists with enhanced lipolytic and metabolic support.
In clinical research, Retatrutide has shown **superior weight reduction effects** compared to Semaglutide and Tirzepatide. It’s currently at the frontier of obesity, type 2 diabetes, and metabolic syndrome research. Due to its glucagon receptor activity, it may also promote lean mass preservation and energy expenditure.
Benefits
- Accelerated weight loss vs other incretin mimetics
- Suppresses hunger and enhances satiety
- Improves blood sugar and insulin sensitivity
- Activates glucagon receptors for fat breakdown
- Potentially preserves lean mass during calorie deficits
Reviews
There are no reviews yet.